S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69

Athersys Stock Forecast, Price & News

-0.04 (-4.78%)
(As of 01/21/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
1.76 million shs
Average Volume
1.20 million shs
Market Capitalization
$187.25 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive ATHX News and Ratings via Email

Sign-up to receive the latest news and ratings for Athersys and its competitors with MarketBeat's FREE daily newsletter.

Athersys logo

About Athersys

Athersys, Inc. engages in the discovery and development of therapies designed to extend and enhance to quality of human life. It offers MultiStem as its stem cell product which provides biological potency and therapeutic effects for distinct diseases and conditions in the cardiovascular, neurological, inflammatory, and immune disease areas. The company was founded by John J. Harrington and Gil van Bokkelen on October 24, 1995 and is headquartered in Cleveland, OH.


Athersys hires pharma, biotech leader as next CEO
January 23, 2022 |  bizjournals.com
Implied Volatility Surging for Athersys (ATHX) Stock Options
December 29, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$1.44 million
Book Value
$0.16 per share


Net Income
$-78.76 million
Pretax Margin




Free Float
Market Cap
$187.25 million

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Social Links


Overall MarketRank

2.13 out of 5 stars

Medical Sector

487th out of 1,418 stocks

Pharmaceutical Preparations Industry

231st out of 684 stocks

Analyst Opinion: 3.0Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -

Athersys (NASDAQ:ATHX) Frequently Asked Questions

Is Athersys a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Athersys in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Athersys stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ATHX, but not buy additional shares or sell existing shares.
View analyst ratings for Athersys
or view top-rated stocks.

How has Athersys' stock price been impacted by COVID-19 (Coronavirus)?

Athersys' stock was trading at $1.28 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ATHX stock has decreased by 37.8% and is now trading at $0.7960.
View which stocks have been most impacted by COVID-19

Are investors shorting Athersys?

Athersys saw a decrease in short interest during the month of December. As of December 31st, there was short interest totaling 10,830,000 shares, a decrease of 34.0% from the December 15th total of 16,420,000 shares. Based on an average trading volume of 1,860,000 shares, the days-to-cover ratio is presently 5.8 days. Currently, 5.0% of the shares of the company are short sold.
View Athersys' Short Interest

When is Athersys' next earnings date?

Athersys is scheduled to release its next quarterly earnings announcement on Thursday, March 24th 2022.
View our earnings forecast for Athersys

How were Athersys' earnings last quarter?

Athersys, Inc. (NASDAQ:ATHX) posted its quarterly earnings data on Monday, November, 15th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.08) by $0.01. The biopharmaceutical company had revenue of $4.79 million for the quarter. During the same quarter last year, the firm posted ($0.11) EPS.
View Athersys' earnings history

What price target have analysts set for ATHX?

1 Wall Street analysts have issued 12 month price targets for Athersys' shares. Their forecasts range from $1.25 to $1.25. On average, they anticipate Athersys' share price to reach $1.25 in the next year. This suggests a possible upside of 57.0% from the stock's current price.
View analysts' price targets for Athersys
or view top-rated stocks among Wall Street analysts.

Who are Athersys' key executives?

Athersys' management team includes the following people:

What is Gil Van Bokkelen's approval rating as Athersys' CEO?

2 employees have rated Athersys CEO Gil Van Bokkelen on Glassdoor.com. Gil Van Bokkelen has an approval rating of 100% among Athersys' employees. This puts Gil Van Bokkelen in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Athersys own?

What is Athersys' stock symbol?

Athersys trades on the NASDAQ under the ticker symbol "ATHX."

How do I buy shares of Athersys?

Shares of ATHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Athersys' stock price today?

One share of ATHX stock can currently be purchased for approximately $0.80.

How much money does Athersys make?

Athersys has a market capitalization of $187.25 million and generates $1.44 million in revenue each year. The biopharmaceutical company earns $-78.76 million in net income (profit) each year or ($0.41) on an earnings per share basis.

How many employees does Athersys have?

Athersys employs 97 workers across the globe.

When was Athersys founded?

Athersys was founded in 1995.

What is Athersys' official website?

The official website for Athersys is www.athersys.com.

Where are Athersys' headquarters?

Athersys is headquartered at 3201 CARNEGIE AVENUE, CLEVELAND OH, 44115.

How can I contact Athersys?

Athersys' mailing address is 3201 CARNEGIE AVENUE, CLEVELAND OH, 44115. The biopharmaceutical company can be reached via phone at (216) 431-9900, via email at [email protected], or via fax at 216-361-9495.

This page was last updated on 1/23/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.